Clinical study of anlotinib combined with CAPEOX/mFOLFOX6 regimen for first-line treatment of advanced colorectal cancer
Objective To explore and analyze the clinical study of the combination of anlotinib and CAPEOX/mFOLFOX6 regimen for first-line treatment of advanced colorectal cancer.Methods Fifty patients with advanced colorectal cancer who received treatment in Ordos City Central Hospital from April 2021 to October 2023 were randomly divided into the control group(receiving first-line treatment with CAPEOX/mFOLFOX6 regimen)and the observation group(receiving first-line treatment with anlotinib combined with CAPEOX/mFOLFOX6 regimen)with 25 cases in each group.The results after the completion of the study were compared and analyzed.Results The short-term effective rate of the observation group was higher than that of the control group(P＜0.05).KPS score of the observation group was higher than the control group after treatment,ZPS score of the control group was higher than that of the observation group,with significant difference(P＜0.05).There was no difference in the incidence of adverse reactions between the two groups(P＞0.05).There was no significant difference in the levels of VEGF and TGF-β between the two groups before treatment(P＞0.05),while the levels of VEGF and TGF-β in the control group were higher than those in the observation group after treatment,and the difference was statistically significant(P＜0.05).There was no significant difference in the levels of T lymphocyte subsets between the two groups before treatment(P＞0.05),while the levels of CD4+,CD8+,and CD4+/CD8+in the observation group were higher than those in the control group after treatment,and the difference was statistically significant(P＜0.05).Conclusion Anlotinib combined with CAPEOX/mFOLFOX6 is effective in the first-line treatment of advanced colorectal cancer patients,and the adverse reactions can be controlled,and the amount of life of patients can be improved to some extent.
AnlotinibCapecitabineOxaliplatinAdvanced stageColorectal cancer
万方数据
维普
